Late-stage clinical companies

Syncona’s late-stage clinical companies have advanced past Phase II clinical trials and working towards delivering potential key value inflection points that have the potential to deliver significant NAV growth

Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases including: leukaemia, lymphoma, multiple myeloma, systemic lupus erythematosus and X-linked retinitis pigmentosa.

The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.